Papers/PMID:40854984
Preliminary, randomized, double-blinded, placebo-controlled cross-over study with resveratrol in hypertensive patients.
Scientific reports2025The record
1 finding drawn from this paper, on 1 compound across 1 endpoint, 1 of them null.
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
resveratrol — no detected effect on diastolic blood pressure (office/clinic)
SuggestiveGrade C, Suggestive. Weak human evidence, or strong evidence in a mismatched population.FindingNull result“Data analyzed using the multivariate ANOVA model revealed that resveratrol’s effects on systolic and diastolic blood pressure were not statistically significant compared with placebo (Table 3).”
Quoted verbatim from Preliminary, randomized, double-blinded, placebo-controlled cross-over study with resveratrol in hypertensive patients.. - Study
- crossover
- Participants
- 16
- Duration
- 4 weeks
- Dose
- 500 mg twice daily, oral
- Population
- pre-hypertensive and stage-1 hypertensive adults aged 20-60 years, Iran; primary outcome; 2 x 2 crossover, 16 completers analysed
Preliminary, randomized, double-blinded, placebo-controlled cross-over study with resveratrol in hypertensive patients.2025PMID:40854984